Roivant Sciences Ltd（ROIV）の株式分析ROIVRoivant Sciences Ltd

Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Roivant Sciences Ltd is a good buy right now due to its recent positive Phase 2 trial results for mosliciguat, which showed a 56.3% improvement in pulmonary vascular resistance, leading analysts to raise their price targets significantly. The current price of $35.44 is well below the average analyst target of $50 to $55, indicating substantial upside potential. However, the company has faced negative earnings with a net income of -265,891,000 USD in Q3 2026, which poses a risk to investors.